Aims: The present study evaluated the effects of sitagliptin-insulin against type 2 diabetes mellitus with neuropathy in rats and possible neuroprotective mechanisms. Methods: Diabetes was induced in 32 adult male albino rats by 6-week high-fat high-sugar diet followed by streptozotocin 30 mg/kg intraperitoneal injection. For 4 weeks thereafter, diabetic rats were divided into 4 groups, each group receiving one of the following daily: vehicle (untreated diabetic), insulin 10 IU/kg SC, sitagliptin 30 mg/kg PO or sitagliptin-insulin. We assessed systolic blood pressure (SBP), blood glucose, serum insulin and advanced glycation end-products (AGEs), thermal hyperalgesia and sciatic nerve tumor necrosis factor-alpha (TNF-α), superoxide dismutase (SOD) and malondialdehyde (MDA) and sciatic histopathology. Results: Compared to untreated and insulin-treated groups, sitagliptin decreased SBP, serum AGEs and sciatic MDA and TNF-α, and increased serum insulin and sciatic SOD, but insulin decreased blood glucose more. Sitagliptin-insulin (greater than sitagliptin or insulin alone) superiorly decreased and increased the above respective parameters, and ameliorated hyperalgesia and sciatic histopathological changes, but was similar to insulin in decreasing blood glucose, and similar to sitagliptin in rising serum insulin. Conclusions: Sitagliptin-insulin combination produced hypoglycemic and neuroprotective effect and ameliorated hyperalgesia, oxidative stress and inflammation more than either drug alone. This combination might have clinical efficacy in uncontrolled type 2 diabetes with neuropathy.

Keywords:
Sitagliptin, Insulin, Diabetes mellitus, Neuropathy, Rats
1.
Lv M, Chen Z, Hu G, Li Q: Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov Today 2015;20:332-346.
2.
Ban K, Hui S, Drucker DJ, Husain M: Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009;3:245-259.
3.
Haluzik M, Frolik J, Rychlik I: Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol 2013;2013:895102.
4.
Nicholson S: The effect of cost sharing on employees with diabetes. Am J Manag Care 2006;12 Spec no.:SP20-SP26.
5.
Pop-Busui R, Sima A, Stevens M: Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 2006;22:257-273.
6.
Said G: Diabetic neuropathy - a review. Nat Clin Pract Neurol 2007;3:331-340.
7.
Obrosova IG: Update on the pathogenesis of diabetic neuropathy. Curr Diab Rep 2003;3:439-445.
8.
Shakeel M: Recent advances in understanding the role of oxidative stress in diabetic neuropathy. Diabetes Metab Syndr 2015;9:373-378.
9.
Gidal BE: New and emerging treatment options for neuropathic pain. Am J Manag Care 2006;12(9 suppl):S269-S278.
10.
Edwards JL, Vincent AM, Cheng HT, Feldman EL: Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008;120:1-34.
11.
Freeman JS: The pathophysiologic role of incretins. J Am Osteopath Assoc 2007;107(suppl):S6-S9.
12.
Hocher B, Reichetzeder C, Alter ML: Renal and cardiac effects of DPP4 inhibitors - from preclinical development to clinical research. Kidney Blood Press Res 2012;36:65-84.
13.
Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS: Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340:248-255.
14.
Deacon CF: Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18.
15.
Nauck MA: Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124(1 suppl):S3-S18.
16.
Seino Y, Yabe D: Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-130.
17.
Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F: Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010;2010:592760.
18.
Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55-72.
19.
Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-496.
20.
Gerich J: DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010;90:131-140.
21.
Charbonnel B, Schweizer A, Dejager S: Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hosp Pract (1995) 2013;41:93-107.
22.
Ren Z, Li W, Zhao Q, Ma L, Zhu J: The impact of 1,25-dihydroxy vitamin D3 on the expressions of vascular endothelial growth factor and transforming growth factor-β₁ in the retinas of rats with diabetes. Diabetes Res Clin Pract 2012;98:474-480.
23.
Tesch GH, Allen TJ: Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007;12:261-266.
24.
Kuhad A, Chopra K: Tocotrienol attenuates oxidative-nitrosative stress and inflammatory cascade in experimental model of diabetic neuropathy. Neuropharmacology 2009;57:456-462.
25.
Abd El Motteleb DM, Elshazly SM: Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor. Eur J Pharmacol 2013;720:158-165.
26.
Liepinsh E, Vilskersts R, Zvejniece L, Svalbe B, Skapare E, Kuka J, Cirule H, Grinberga S, Kalvinsh I, Dambrova M: Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. Br J Pharmacol 2009;157:1549-1556.
27.
Shabani M, Nazeri M, Parsania S, Razavinasab M, Zangiabadi N, Esmaeilpour K, Abareghi F: Walnut consumption protects rats against cisplatin-induced neurotoxicity. Neurotoxicology 2012;33:1314-1321.
28.
Makaritsis KP, Gavras H, Du Y, Chobanian AV, Brecher P: Alpha1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension 1998;32:1044-1048.
29.
Reid JL, Zivin JA, Kopin IJ: Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res 1975;37:569-579.
30.
Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
31.
Wu YB, Shi LL, Wu YJ, Xu WH, Wang L, Ren MS: Protective effect of gliclazide on diabetic peripheral neuropathy through Drp-1 mediated-oxidative stress and apoptosis. Neurosci Lett 2012;523:45-49.
32.
Vasavada N, Agarwal R: Role of oxidative stress in diabetic nephropathy. Adv Chronic Kidney Dis 2005;12:146-154.
33.
Murai K, Katsuno T, Miyagawa J, Matsuo T, Ochi F, Tokuda M, Kusunoki Y, Miuchi M, Namba M: Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data. Drugs R D 2014;14:301-308.
34.
Otsuka Y, Yamaguchi S, Furukawa A, Kosuda M, Nakazaki M, Ishihara H: Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Endocr J 2015;62:133-143.
35.
Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM: A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000;49:1390-1394.
36.
Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR: Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008;233:4-11.
37.
Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE: Natural history of diabetic gastroparesis. Diabetes Care 1999;22:503-507.
38.
Satchell SC, Tooke JE: What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008;51:714-725.
39.
Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH: A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-966.
40.
Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH: Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007;203:293-301.
41.
Salcedo I, Tweedie D, Li Y, Greig NH: Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012;166:1586-1599.
42.
During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173-1179.
43.
Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK: New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 2004;1035:290-315.
44.
Perry T, Greig NH: Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2005;2:377-385.
45.
Girach A, Vignati L: Diabetic microvascular complications - can the presence of one predict the development of another? J Diabetes Complications 2006;20:228-237.
46.
Campbell RK, White JR Jr: More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ 2008;34:518-534.
47.
Martin JH, Deacon CF, Gorrell MD, Prins JB: Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience. Intern Med J 2011;41:299-307.
48.
Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D: Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009;94:1843-1852.
49.
Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W: Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:699-706.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.